Arq - Q3 2026 Earnings Call - ARQ INC

Explicit Guidance:

• Full-Year 2026 Adjusted EBITDA: Tightened range to $19–$20 million (from $17–$20 million), with results converging toward the top end of the original guidance.
• Full-Year 2026 Revenue: Reiterated range of $120–$125 million.
• Full-Year 2026 CapEx: Reiterated guidance of $8–$10 million.
• 2027 Adjusted EBITDA Run Rate: Expects to exit 2027 at a run rate of approximately $30 million, driven by organic growth, cost efficiencies, and the inclusion of PAC for PFAS, without relying on Granular Activated Carbon (GAC) CapEx.
• 2027 Formal Guidance: To be provided early in the new year; management expects "meaningful orders" for PAC for PFAS to commence in 2027, with revenue contribution expected to be "back-end loaded."
• Credit Refinancing Target: Aims to complete refinancing of the mid-cap financial credit facility within six months to lower the cost of capital and simplify reporting.
• Corbin Monetization: Expects the process to potentially conclude within 12 months, though not factored into 2027 financial expectations.

Business-Segment Outlook:

• Foundational PAC Business: Expects continued organic growth in volumes and pricing through contract renewals and efficiency gains; margins remain strong at 39.7% in Q3 2026.
• PAC for PFAS (Primary Driver): Viewed as the immediate priority for 2027 growth; product priced "materially above" traditional PAC average selling prices. Addresses lower-level PFAS contamination and taste/odor issues; potential to reduce GAC change-out frequency in combined applications.
• Granular Activated Carbon (GAC): Deferred as a near-term revenue driver; strategic optimization review is complete. Decision to proceed is contingent on funding solutions and acceptable return profiles, not on PAC for PFAS adoption timing. GAC remains an optionality for the 2029–2031 compliance window.
• Corbin Asset: Active monetization efforts ongoing; identified buyer universe includes asphalt producers, with secondary opportunities in rare earths, synthetic graphite, silicone wafers, and energy storage feedstock. Currently carries $1.9M in escrow, $1.2M in annual OpEx, and $1.4M in annual SG&A.
• Product Pipeline: Plans to expand PFAS solutions beyond PAC for PFAS (e.g., GAC) as the 2029–2031 compliance deadlines approach.

Market and Competitive Outlook:

• PFAS Market Dynamics: Market described as "robust" with rising prices; municipal customers are proactively seeking remediation to avoid reputational risk, regardless of strict regulatory timetables.
• Regulatory Catalysts: April 2027 EPA monitoring and reporting deadline is driving immediate customer demand. 2029–2031 compliance deadlines expected to further expand the addressable market.
• Addressable Market Size: Conservatively estimated at 160 million pounds per year by 2029 for PAC for PFAS; expected to grow as compliance deadlines near.
• Pricing Power: Confirmed anecdotal price increases across the activated carbon industry; PAC for PFAS sales have exceeded traditional ASPs.
• Customer Relationships: Expectation of longer-term contracts (single and multi-year) and customized solutions as utilities transition from monitoring to compliance.

Macro / Industry Outlook:

• Regulatory Environment: Management anticipates the regulatory timetable for PFAS reporting and compliance will accelerate customer adoption of remediation solutions.
• Sector Trends: Water utilities are prioritizing immediate compliance over waiting for final mandates due to reputational risks.
• Capital Markets: Expectation that a refined, simpler credit facility will provide increased liquidity and lower costs compared to the current facility (historically signed at ~$7M EBITDA vs. current $20M guidance).

Strategic Initiatives:

• Cost & Efficiency Program: Ongoing review identified 15+ opportunities to improve efficiency, reduce costs, and unlock liquidity across eight departments; expects sustainable SG&A reductions and working capital improvements in 2027.
• Balance Sheet Optimization: Refinancing mid-cap credit facility to reduce reporting burden and lower cost of capital; target completion within six months.
• Asset Monetization: Accelerating the sale of the Corbin site; potential to meaningfully benefit balance sheet and operating results.
• Capital Allocation: Prioritizing "little to no CapEx" growth via PAC for PFAS; GAC construction deferred until a funding solution is secured.
• Management Structure: Recent appointments of new CFO (Jamon) and CAO (Peter Wawino) to drive financial efficiency; new VP of Operations (Thad Ratliff) to lead existing operations ahead of any potential GAC construction.
• Intellectual Property: Pending patent protection for advanced PAC for PFAS water carbons.

Risks and Headwinds to Outlook:

• Market Volatility: Specific volumes and pricing for PAC for PFAS are still being defined; "early" stage of commercialization.
• Regulatory Uncertainty: Potential delays or changes in EPA reporting/compliance dates could impact the timing of customer orders.
• Capital Constraints: GAC expansion is dependent on securing an "acceptable funding solution"; no commitment made on timing.
• Monetization Timelines: Sale of Corbin asset is subject to a "specialized" buyer universe; could take longer than expected.
• Capacity Constraints: If demand outpaces capacity, company may eliminate lower-margin segments; management views capacity constraints as a "pleasant problem" but notes potential need to carve out low-end volumes.
• SG&A Volatility: Past increases in incentive compensation and legal fees noted; future expense levels subject to optimization execution.

Management Tone on the Future:

• Confidence Level: High confidence in near-term execution, citing a "strong year, not just a great quarter" and 10 consecutive quarters of positive adjusted EBITDA.
• Strategic Clarity: Emphasis on "measured" but positive outlook regarding PFAS; clear prioritization of PAC for PFAS over GAC for 2027 growth.
• Investor Relations: Stated priority on rebuilding credibility by "meeting or beating" targets; views current stock price as "severely undervalued" relative to replacement value and earnings potential.
• Financial Outlook: Expects to deliver "material near-term growth" without significant additional CapEx; confident in achieving $30M EBITDA run rate by end of 2027.
• Caveats: Repeatedly notes that 2027 guidance is "back-end loaded" and that specific market size/volume details will be refined as testing continues.

Miscellaneous:

• Testing Status: Over a dozen opportunities identified for PAC for PFAS; testing typically takes 1–3 months with contract discussions occurring simultaneously.
• Operational Success: Q3 2026 adjusted EBITDA of $8.8M already exceeded full-year 2025 EBITDA ($13M) reported previously, though this was before any PAC for PFAS contribution.
• R&D Spend: Reduced from $2.6M in Q3 2025 to $0.8M in Q3 2026 due to the absence of GAC ramp-up expenses.
• Net Income: Turned profitable in Q3 2026 ($2.5M) vs. a net loss in Q3 2025, bolstered by NOLs to convert operating profit to net income.